据介绍，今年3月24日、4月25日，广陵区市场监管局收到扬州市医保局广陵分局移交的两批线索。经核 查发现，该区一诊所于2月16日销售了两盒复方丹参滴丸，每盒50元；2月19日、2月26日分别销售了3盒 和2盒麝香保心丸，每盒46元。该诊所不能提供涉案药品的进货凭证和供货者资料。 执法人员表示，当事人的行为构成从无资质企业购进药品，涉嫌二次销售。鉴于其系初次违法、积极配 合调查、主动提供材料且未造成危害后果，本着处罚与教育相结合、过罚相当原则，执法部门依法作出 没收违法所得并罚款2000元的决定，并将线索移交纪委监察部门。 市场监管部门正告，复方丹参滴丸、麝香保心丸是关乎群众健康的心血管常用药，质量安全至关重要。 近年来，随着医保报销水平提高、目录范围扩大，群众用药更加便捷，但也让不法分子有机可乘。部分 药贩通过"高价回收"诱导参保人参与药品买卖，形成医保"回流药"非法链条。本案中基层医疗机构出现 此类违法行为，性质更为严重。 扬子晚报网11月22日讯(通讯员广市监记者陈咏)21日，扬州市广陵区市场监管局曝光一起药品安全违法 典型案例。 市场监管部门提醒，药品追溯码是每盒药品的"电子身份证"，具有唯一性。正规药 ...

Core Viewpoint - The article highlights the serious threat posed by "reflow drugs," which are pharmaceuticals that re-enter the market through unofficial channels, jeopardizing consumer safety and undermining the integrity of the healthcare system [1][2]. Group 1: Impact on Consumer Safety and Market Integrity - Reflow drugs pose significant risks to public health, as they may be expired or stored improperly, leading to ineffective treatment or worsening of conditions [2]. - The presence of reflow drugs disrupts the legitimate pharmaceutical market, harming the interests of legitimate companies and eroding healthcare funds [2]. - The unique traceability codes on drug packages serve as a safeguard against counterfeit and reflow drugs, with multiple scans indicating potential fraud [2]. Group 2: Law Enforcement and Regulatory Actions - The National Healthcare Security Administration has initiated a special action to combat the sale of reflow drugs, uncovering over 30,000 suspicious traceability code leads across various institutions [2][7]. - Notable cases include a pharmacy in Hunan that sold drugs with traceability codes linked to multiple regions, raising concerns about the legitimacy of their inventory [2]. - The article details organized crime involving reflow drugs, with significant financial implications, including cases where criminal groups operated across regions with transactions exceeding 100 million yuan [3]. Group 3: Mechanisms of Reflow Drug Distribution - The article outlines the methods by which reflow drugs are sold, including individuals purchasing drugs through insurance and reselling them, as well as collusion between drug dealers and pharmacies [4]. - A specific case illustrates how an individual exploited insurance accounts to sell drugs at below-market prices, leading to legal consequences [4][11]. - The article also describes how some pharmaceutical companies engage in fraudulent practices, such as falsifying invoices to disguise reflow drugs as legitimate products [5][12]. Group 4: Regulatory Framework and Future Measures - The establishment of a comprehensive drug traceability system is underway, with all medical institutions required to upload traceability data by January 2026 [7]. - The article notes that as of August, over 661.51 billion traceability codes have been collected, indicating a tightening regulatory framework against reflow drugs [7]. - Experts suggest that a unified data standard and deeper integration of regulatory platforms are necessary to effectively combat the issue of reflow drugs [8]. Group 5: Public Awareness and Legal Consequences - The article emphasizes the importance of public engagement in monitoring drug sales through traceability codes to ensure safety and protect healthcare funds [9]. - Legal experts advocate for stricter definitions and penalties for those involved in the reflow drug trade, including potential inclusion on blacklists for offenders [9]. - The article concludes that the current regulatory environment presents low costs for offenders and high costs for enforcement, necessitating legal reforms to deter such activities [9].

Core Insights - The provincial medical insurance flying inspections are being initiated across various regions, focusing on the issue of "return drugs" and fraudulent practices in medical insurance [1][2][3] Group 1: Inspection Overview - The provincial flying inspections will cover all medical service behaviors and costs from January 1, 2023, to December 31, 2024, with the possibility of extending checks to previous years or 2025 [1] - The inspections are organized in a collaborative manner involving provincial and municipal levels, with teams typically consisting of around 50 members, including experts from various fields [2] Group 2: Focus Areas - Key areas of inspection include medical institutions, retail pharmacies, insured individuals, and medical insurance handling agencies, with specific attention on self-inspection results in nine medical fields [3] - The "return drug" issue is highlighted, with a focus on tracking drug traceability codes to combat illegal resale practices [3][4] Group 3: Regulatory Actions - The inspections will lead to immediate reporting to drug regulatory authorities for any discovered illegal activities, including the sale of return drugs and counterfeit medications [4] - The National Medical Insurance Administration has previously recovered over 8 billion yuan through similar inspections, demonstrating the effectiveness of these regulatory measures [2]